Allovir IncNASDAQ:ALVRNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.8085
- TODAY'S CHANGE (%)0.0095 (1.1890%)
- Bid / Lots0.7965/ 3
- Ask / Lots0.8085/ 3
- Open / Previous Close0.7710 / 0.7990
- Day Range
- 52 Week Range
- Volume74,920
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALVR |
|---|---|---|
| 09:32 ET | 2168 | 0.771 |
| 09:34 ET | 255 | 0.784 |
| 09:39 ET | 1000 | 0.76565 |
| 09:41 ET | 300 | 0.7702 |
| 09:48 ET | 499 | 0.785 |
| 10:12 ET | 500 | 0.7935 |
| 10:17 ET | 100 | 0.7945 |
| 10:19 ET | 100 | 0.799 |
| 10:21 ET | 353 | 0.7995 |
| 10:24 ET | 600 | 0.7994 |
| 10:33 ET | 550 | 0.7974 |
| 10:42 ET | 300 | 0.79 |
| 10:44 ET | 200 | 0.7924 |
| 10:46 ET | 100 | 0.79025 |
| 10:50 ET | 1100 | 0.7994 |
| 10:55 ET | 100 | 0.7994 |
| 11:02 ET | 506 | 0.7994 |
| 11:08 ET | 6802 | 0.8 |
| 11:09 ET | 2030 | 0.8 |
| 11:20 ET | 600 | 0.8 |
| 11:36 ET | 600 | 0.8 |
| 11:42 ET | 617 | 0.8 |
| 11:44 ET | 300 | 0.8 |
| 11:54 ET | 7632 | 0.7811 |
| 12:03 ET | 800 | 0.7965 |
| 12:05 ET | 100 | 0.7968 |
| 12:12 ET | 530 | 0.7886 |
| 12:14 ET | 400 | 0.7968 |
| 12:25 ET | 2786 | 0.8 |
| 12:27 ET | 555 | 0.8 |
| 12:39 ET | 707 | 0.8 |
| 12:41 ET | 600 | 0.8 |
| 12:50 ET | 300 | 0.7999 |
| 12:57 ET | 900 | 0.7969 |
| 01:01 ET | 100 | 0.7999 |
| 01:06 ET | 2726 | 0.7999 |
| 01:12 ET | 2221 | 0.8 |
| 01:32 ET | 300 | 0.8 |
| 01:42 ET | 400 | 0.8 |
| 01:50 ET | 2483 | 0.8 |
| 01:51 ET | 178 | 0.8 |
| 01:53 ET | 9461 | 0.80115 |
| 01:57 ET | 605 | 0.7968 |
| 02:00 ET | 666 | 0.8057 |
| 02:02 ET | 102 | 0.8012 |
| 02:06 ET | 247 | 0.8058 |
| 02:08 ET | 1529 | 0.8 |
| 02:09 ET | 100 | 0.8032 |
| 02:13 ET | 100 | 0.8032 |
| 02:15 ET | 300 | 0.806 |
| 02:24 ET | 100 | 0.806 |
| 02:26 ET | 300 | 0.806 |
| 02:36 ET | 300 | 0.806 |
| 02:38 ET | 100 | 0.806 |
| 02:47 ET | 100 | 0.806 |
| 02:49 ET | 400 | 0.8059 |
| 02:51 ET | 100 | 0.7969 |
| 02:56 ET | 1100 | 0.8 |
| 02:58 ET | 300 | 0.806 |
| 03:02 ET | 2101 | 0.809 |
| 03:03 ET | 200 | 0.8096 |
| 03:12 ET | 356 | 0.8096 |
| 03:16 ET | 400 | 0.8096 |
| 03:18 ET | 1530 | 0.8086 |
| 03:21 ET | 400 | 0.8028 |
| 03:23 ET | 469 | 0.8086 |
| 03:27 ET | 258 | 0.8085 |
| 03:34 ET | 400 | 0.8085 |
| 03:38 ET | 1000 | 0.8 |
| 03:39 ET | 1214 | 0.8085 |
| 03:41 ET | 2400 | 0.8085 |
| 03:43 ET | 860 | 0.8085 |
| 03:45 ET | 400 | 0.8085 |
| 03:48 ET | 177 | 0.8085 |
| 03:50 ET | 311 | 0.8085 |
Sep 16, 2024
Kuehn Law Encourages Investors of AlloVir, Inc. to Contact Law Firm, from 11:16AM ET on Monday Sep 16, 2024 by Dow Jones
11:16AM ET on Monday Sep 16, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Allovir Inc | 86.5M | -0.7x | --- |
Bioatla Inc | 87.5M | -0.8x | --- |
Sellas Life Sciences Group Inc | 84.9M | -1.3x | --- |
Genelux Corp | 84.3M | -2.3x | --- |
Hillevax Inc | 91.1M | -0.5x | --- |
Tevogen Bio Holdings Inc | 81.7M | 1.0x | --- |
Company Information
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
Contact Information
- Headquarters
- 1100 Winter StreetWALTHAM, MA, United States 02451
- Phone
- 617-433-2605
- Fax
- 302-655-5049
Executives
- Executive Chairman of the Board
- David Hallal
- President, Chief Financial Officer, Director
- Vikas Sinha
- Chief Executive Officer, Director
- Diana Brainard
- Co-Founder, Chief Scientific Officer
- Ann Leen
- Chief Accounting Officer
- Brett Hagen
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $86.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 115.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.78 |
EPS | $-1.23 |
Book Value | $1.28 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
